Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$92.34
+2.3%		$77.49
$54.11
▼
$92.56
$34.85B1.415.73 million shs3.48 million shs
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$74.82
+1.0%		$66.61
$58.75
▼
$89.77
$33.80B0.694.62 million shs2.25 million shs
Glaukos Corporation stock logo
GKOS
Glaukos
$185.66
+0.4%		$157.38
$73.16
▼
$191.62
$10.91B0.78961,319 shs440,096 shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$556.93
+2.0%		$560.01
$518.55
▼
$769.98
$43.88B1.54643,864 shs485,742 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
0.00%+2.89%+31.02%+28.07%+13.06%
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
0.00%+1.53%+20.70%+16.49%+1.29%
Glaukos Corporation stock logo
GKOS
Glaukos
0.00%+0.35%+22.01%+53.50%+104.26%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.00%+1.08%+3.26%-0.44%-12.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$92.34
+2.3%		$77.49
$54.11
▼
$92.56
$34.85B1.415.73 million shs3.48 million shs
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$74.82
+1.0%		$66.61
$58.75
▼
$89.77
$33.80B0.694.62 million shs2.25 million shs
Glaukos Corporation stock logo
GKOS
Glaukos
$185.66
+0.4%		$157.38
$73.16
▼
$191.62
$10.91B0.78961,319 shs440,096 shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$556.93
+2.0%		$560.01
$518.55
▼
$769.98
$43.88B1.54643,864 shs485,742 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
0.00%+2.89%+31.02%+28.07%+13.06%
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
0.00%+1.53%+20.70%+16.49%+1.29%
Glaukos Corporation stock logo
GKOS
Glaukos
0.00%+0.35%+22.01%+53.50%+104.26%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.00%+1.08%+3.26%-0.44%-12.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.89
Moderate Buy$88.71-3.93% Downside
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
2.48
Hold$77.733.89% Upside
Glaukos Corporation stock logo
GKOS
Glaukos
2.79
Moderate Buy$178.08-4.08% Downside
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.60
Moderate Buy$747.0034.13% Upside

Current Analyst Ratings Breakdown

Latest GKOS, IDXX, DXCM, and GEHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
Glaukos Corporation stock logo
GKOS
Glaukos
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$193.00 ➝ $202.00
8/19/2026
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$79.00
8/12/2026
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
8/11/2026
DexCom, Inc. stock logo
DXCM
DexCom
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/11/2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$800.00 ➝ $710.00
8/11/2026
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/5/2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$650.00 ➝ $670.00
8/5/2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$620.00 ➝ $670.00
8/4/2026
DexCom, Inc. stock logo
DXCM
DexCom
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$86.00 ➝ $96.00
8/3/2026
DexCom, Inc. stock logo
DXCM
DexCom
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$82.00 ➝ $90.00
7/31/2026
DexCom, Inc. stock logo
DXCM
DexCom
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.66B7.47$2.77 per share33.35$6.95 per share13.29
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$20.63B1.64$5.88 per share12.73$24.33 per share3.08
Glaukos Corporation stock logo
GKOS
Glaukos
$507.44M21.58N/AN/A$11.57 per share16.05
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$4.30B10.19$15.08 per share36.92$20.47 per share27.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.5336.5029.981.5620.12%35.94%14.75%10/29/2026 (Estimated)
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$2.08B$4.3617.1613.832.169.33%20.12%5.74%11/4/2026 (Estimated)
Glaukos Corporation stock logo
GKOS
Glaukos
-$187.69M-$3.25N/A364.04N/A-30.68%-6.37%-4.78%11/4/2026 (Estimated)
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$1.06B$14.2239.1733.512.9725.03%71.96%33.60%11/2/2026 (Estimated)

Latest GKOS, IDXX, DXCM, and GEHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.94$4.27+$0.33$4.27$1.20 billion$1.22 billion
7/30/2026Q2 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.6110$0.70+$0.0890$0.64$1.29 billion$1.31 billion
7/29/2026Q2 2026
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$1.04$1.13+$0.09$1.24$5.26 billion$5.30 billion
7/29/2026Q2 2026
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.2105-$0.14+$0.0705-$0.31$150.93 million$185.61 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$0.140.19%N/A3.21%1 Years
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A

Latest GKOS, IDXX, DXCM, and GEHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/30/2026
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
quarterly$0.03500.23%7/24/20267/24/20268/14/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.47
1.73
1.43
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
0.92
1.26
0.97
Glaukos Corporation stock logo
GKOS
Glaukos
0.10
5.04
4.46
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.19
1.17
0.87

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
82.06%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
0.36%
Glaukos Corporation stock logo
GKOS
Glaukos
5.90%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000377.36 million376.30 millionOptionable
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
54,000451.69 million450.06 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
1,09458.98 million55.50 millionOptionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11,00078.78 million78.16 millionOptionable

Recent News About These Companies

Great Lakes Advisors LLC Takes $2.10 Million Position in IDEXX Laboratories, Inc. $IDXX
August 22 at 4:01 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-great-lakes-advisors-llc-takes-210-million-position-in-idexx-laboratories-inc-idxx-2026-08-22/
Bank of New York Mellon Corp Purchases New Holdings in IDEXX Laboratories, Inc. $IDXX
August 22 at 3:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-purchases-new-holdings-in-idexx-laboratories-inc-idxx-2026-08-22/
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
August 21 at 10:56 AM  |  zacks.comhttps://www.zacks.com/stock/news/2978303/is-it-a-prudent-move-to-retain-idexx-stock-in-your-portfolio-now?cid=cs-stocknewsapi-ft-analyst_blog|rank_focused-2978303
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
August 20 at 12:41 PM  |  zacks.comhttps://www.zacks.com/stock/news/2977771/idxx-raises-2026-eps-outlook-as-diagnostic-growth-and-margins-improve?cid=cs-stocknewsapi-ft-analyst_blog_plus|zer_report_insights-2977771
Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding
August 20 at 12:30 PM  |  insidermonkey.comhttps://www.insidermonkey.com/blog/rationale-behind-baron-focused-growth-funds-idexx-laboratories-idxx-holding-1821130/
Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding
August 20 at 11:50 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/rationale-behind-baron-focused-growth-154228414.html
Flossbach Von Storch SE Invests $9.09 Million in IDEXX Laboratories, Inc. $IDXX
August 20 at 4:16 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-flossbach-von-storch-se-invests-909-million-in-idexx-laboratories-inc-idxx-2026-08-20/
Danske Bank A S Buys New Stake in IDEXX Laboratories, Inc. $IDXX
August 20 at 4:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-danske-bank-a-s-buys-new-stake-in-idexx-laboratories-inc-idxx-2026-08-20/
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
August 19, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2976926/is-idxx-worth-buying-as-growth-strength-meets-a-premium-valuation?cid=cs-stocknewsapi-ft-analyst_blog_plus|zer_report_insights-2976926
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors despite daily gains
August 19, 2026  |  marketwatch.comhttps://www.marketwatch.com/data-news/idexx-laboratories-inc-stock-underperforms-tuesday-when-compared-to-competitors-despite-daily-gains-d1e4c3f8-88369e34720a
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
August 18, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4937492-idexx-laboratories-inc-idxx-analyst-investor-day-transcript
Plato Investment Management Ltd Takes $1.48 Million Position in IDEXX Laboratories, Inc. $IDXX
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-plato-investment-management-ltd-takes-148-million-position-in-idexx-laboratories-inc-idxx-2026-08-18/
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
August 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30963454
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Rating of "Moderate Buy" from Analysts
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/idexx-laboratories-inc-nasdaqidxx-receives-average-rating-of-moderate-buy-from-analysts-2026-08-16/
IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/idexx-laboratories-targets-45b-pet-diagnostics-opportunity-with-ai-cancer-tests-2026-08-14/
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day - Slideshow
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936889-idexx-laboratories-inc-idxx-analyst-investor-day-slideshow
Handelsbanken Fonder AB Grows Position in IDEXX Laboratories, Inc. $IDXX
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-handelsbanken-fonder-ab-grows-position-in-idexx-laboratories-inc-idxx-2026-08-13/
Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/strong-q2-2026-results-cardiac-021011441.html
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
August 12, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2973463/here-s-why-idexx-laboratories-idxx-is-a-strong-growth-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_growth_score-2973463
NewEdge Advisors LLC Acquires 5,761 Shares of IDEXX Laboratories, Inc. $IDXX
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-newedge-advisors-llc-acquires-5761-shares-of-idexx-laboratories-inc-idxx-2026-08-10/
Seilern Investment Management Ltd Purchases 16,729 Shares of IDEXX Laboratories, Inc. $IDXX
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seilern-investment-management-ltd-purchases-16729-shares-of-idexx-laboratories-inc-idxx-2026-08-09/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
GE HealthCare logo displayed on a wall beside an MRI scanner in a futuristic imaging suite.
GE HealthCare Stock Climbs on Vital Diagnostics Demand
By Jeffrey Neal Johnson | August 1, 2026
DexCom stock logo

DexCom NASDAQ:DXCM

$92.34 +2.12 (+2.35%)
As of 08/21/2026 04:00 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

GE HealthCare Technologies stock logo

GE HealthCare Technologies NASDAQ:GEHC

$74.82 +0.76 (+1.03%)
As of 08/21/2026 04:00 PM Eastern

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Glaukos stock logo

Glaukos NYSE:GKOS

$185.66 +0.77 (+0.42%)
As of 08/21/2026 03:58 PM Eastern

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$556.93 +11.07 (+2.03%)
As of 08/21/2026 04:00 PM Eastern

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas